Cancer and fibrosis therapy developer Forbius has agreed to be acquired by Bristol Myers Squibb nine years after it was spun off by YM BioSciences.
Pharmaceutical firm Bristol Myers Squibb (BMS) has agreed to purchase Forbius, a US-based cancer and fibrosis drug developer spun off by pharmaceutical company YM BioSciences, for an undisclosed amount.
Formed in 2011, Forbius has assembled a clinical and preclinical-stage portfolio of drug candidates for cancer and fibrosis, a disease in which connective tissue grown in place of normal organ tissue leads to permanent scarring.
The company’s most advanced product candidate, Avid200, has completed phase 1a clinical trials as a potential…
